Betadine Skin Cleanser 40mg/ml cutaneous solution

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Povidone-iodine

제공처:

Ayrton Saunders Ltd

ATC 코드:

D08AG; D08AG02

INN (International Name):

Povidone-iodine

복용량:

40 milligram(s)/millilitre

약제 형태:

Cutaneous solution

처방전 유형:

Product not subject to medical prescription

치료 영역:

Iodine products; povidone-iodine

승인 상태:

Not marketed

승인 날짜:

1975-11-25

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Betadine Skin Cleanser 40mg/ml cutaneous solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains 40 mg povidone iodine.
For excipients see Section 6.1.
3 PHARMACEUTICAL FORM
Cutaneous Solution.
Golden brown, clear viscous liquid.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the disinfection and cleansing of skin in the management of
superficial infections.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Apply to thoroughly wet skin, then rinse, twice daily or as directed
by a physician.
4.3 CONTRAINDICATIONS
Use in patients with hypersensitivity to iodine.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Use of the preparation may interfere with tests of thyroid function.
If there is aggravation of the condition or no improvement consult the
doctor.
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None stated.
4.6 FERTILITY, PREGNANCY AND LACTATION
Regular use of povidone-iodine should be avoided in pregnant or
lactating women as absorbed iodine can cross the
placental barrier and can be secreted into breast milk.
4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
None known.
4.8 UNDESIRABLE EFFECTS
Use of this preparation may interfere with tests of thyroid function.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_2_
_/_
_1_
_2_
_/_
_2_
_0_
_1_
_1_
_C_
_R_
_N_
_ _
_2_
_1_
_0_
_6_
_4_
_2_
_7_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.9 OVERDOSE
In the case of accidental ingestion of l